Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 18, pp. 3641-3649
Open Access | Times Cited: 16

Showing 16 citing articles:

Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 158
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. e1-e22
Closed Access | Times Cited: 23
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang, Shun‐Qing Liang, Ralph A. Schmid, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 119
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Iris Z. Uras, Herwig P. Moll, Emilio Casanova
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4325-4325
Open Access | Times Cited: 115
Targeting MEK in non-small cell lung cancer
Matthew S Lara, Collin M. Blakely, Jonathan W. Riess
Current Problems in Cancer (2024) Vol. 49, pp. 101065-101065
Open Access | Times Cited: 5
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Identification of prognostic biomarker of non-small cell lung cancer based on mitochondrial permeability transition-driven necrosis-related genes and determination of anti-tumor effect of ARL14
Zhifei Ma, Wen Chen, Aiping Zhang, et al.
Hereditas (2025) Vol. 162, Iss. 1
Open Access
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access
Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway
Miao Hao, Tian‐Xing Zhang, Dan Dong, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access
Current perspectives of KRAS in non-small cell lung cancer
Ethan Harris, Rajat Thawani
Current Problems in Cancer (2024) Vol. 51, pp. 101106-101106
Closed Access | Times Cited: 3
My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype
Yadi Zhou, Junfei Zhao, Jiansong Fang, et al.
Genome biology (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
Joshua C. Rosen, Jessica Weiss, Nhu‐An Pham, et al.
Translational Oncology (2021) Vol. 14, Iss. 10, pp. 101179-101179
Open Access | Times Cited: 17
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Francesca Jacobs, Massimiliano Cani, Umberto Malapelle, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6332-6332
Open Access | Times Cited: 13
The safety and efficacy of binimetinib for lung cancer: a systematic review
Mahdi Zahmatyar, Ladan Kharaz, Negin Abiri Jahromi, et al.
BMC Pulmonary Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
TargetingKRAS-Mutated NSCLC: Novel TKIs and Beyond
David J. Cantor, Charu Aggarwal
Clinical Cancer Research (2023) Vol. 29, Iss. 18, pp. 3563-3565
Open Access
Page 1

Scroll to top